Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association
June 25 2021 - 8:45AM
Business Wire
- Conference programming reaffirms Dexcom CGM as central to
improved diabetes management
- Showcases benefits of Dexcom CGM for broader populations beyond
those on mealtime insulin
- Demonstrates the impact of Dexcom real-time CGM for inpatient
monitoring
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring (CGM) for people with diabetes,
announced today featured research and data presentations that will
headline the 81st Scientific Sessions of the American Diabetes
Association (ADA) virtual conference held June 25-29, 2021.
“Year over year it is remarkable to see the growing body of
research and data that continues to show CGM is central to optimal
diabetes management, regardless of how a person administers
insulin,” said Jake Leach, chief technology officer at Dexcom. “In
addition, we are now seeing more and more evidence of the benefits
of CGM for broader populations, including people with Type 2
diabetes who are not using insulin, inpatient care, and even for
general health and wellness.”
Key posters and research presented at ADA include:
Dexcom CGM Driven Outcomes:
- Poster 69-LB, “Nonadjunctive Continuous Glucose Monitoring to
Control Hypoglycemia (COACH)” (Stayce Beck)
- Poster 76-LB, “Baseline A1C Values and Magnitude of A1C
Reductions during Nonadjunctive Continuous Glucose Monitoring Use
in the COACH Study” (Stayce Beck)
Dexcom Feature Engagement and Performance:
- Poster 601-P, “Time-in-Range Is Impacted More by High Threshold
Alerts than by Screen View Frequency for Users of a Real-Time CGM
System” (Robert Dowd)
- Poster 622-P, “Frequent Engagement with Retrospective Real-Time
CGM Data Is Associated with Improved Glycemic Control” (Joost van
der Linden)
- Poster 70-LB, “Continuous Glucose Monitoring Data Sharing in
Older Adults with Type 1 Diabetes and Their Care Partners” (Nancy
A. Allen)
Type 2 Diabetes Health Outcomes, Economic Outcomes and Market
Access:
- Presentation: Breaking the Glass Ceiling With New Clinical
Approaches for rtCGM. Moderated by Guillermo Umpierrez, MD on
Saturday, June 26, 2021, 12:30 – 1:45 p.m. ET. Speakers include:
Richard Bergenstal, MD; Nicole Ehrhardt, MD; Thomas Martens,
MD
- Presentation: Clinical Evidence and Practical Applications
Implementing Real-Time Continuous Glucose Monitoring (rt-CGM) in
Adults With Type 2 Diabetes (T2D). Moderated by Christine Pospisil
RD, LD, CDCES, Monday, June 28, 2021, 1-2 p.m. ET. Speakers
include: Thomas Blevins, MD, ENCU, FACE, FNLA, Thomas Grace, MD,
Kristyn Milburn, MSN, NP-C, BC-ADM, CDCES.
- Poster 66-LB: “Real-Time Continuous Glucose Monitor (RTCGM) Use
Associated with Decreased Diabetes Medical Costs for Patients with
Type 2 Diabetes (T2D)” (Greg Norman)
- Poster 77-LB, “A Retrospective Analysis of the Association
between HbA1c and Continuous Glucose Monitor Use for U.S. Patients
with Type 2 Diabetes” (Greg Norman)
- Poster 597-P, “Long-Term A1C Outcomes with and without
Intermittent CGM Use in Adults with T2D Participating in the Onduo
Program” (Jennifer E. Layne)
- Poster 600-P, “Real-Time CGM Coverage Eligibility Should
Include Type 2 Diabetes Patients Treated with Less-Intensive
Therapy” (Thomas Grace)
Patient Monitoring:
- Presentation: Breaking the Glass Ceiling With New Clinical
Approaches for rtCGM. Moderated by Guillermo Umpierrez, MD on
Saturday, June 26, 2021, 12:30 – 1:45 p.m. ET. Speakers include:
Richard Bergenstal, MD; Nicole Ehrhardt, MD; Thomas Martens,
MD
- Poster 613-P, “Performance Evaluation of Dexcom G6 Continuous
Glucose Monitoring and Capillary Blood Glucose after Hospital
Discharge in Patients with Diabetes” (Rodolfo J. Galindo)
- Poster 619-P, “Comparison of Dexcom G6 Continuous Glucose
Monitoring and Point-of-Care Blood Glucose Testing in Hospitalized
Patients with Diabetes” (Georgia M. Davis)
Health and Wellness:
- Oral 154-OR: “People Who Get More Hours of Sleep Have Lower
Mean Glucose: Analysis of Continuous Glucose Monitoring and Fitbit
Data in a Free-Living Population without Diabetes” (Margaret
Crawford) (Sunday, June 27, 2021 from 9:45 AM to 10:00 AM)
In addition, there are more than a dozen ADA posters and
presentations highlighting the health outcomes and quality of life
improvements for automated insulin delivery systems that integrate
with Dexcom CGM.
For more information about the 81st Scientific Sessions of the
American Diabetes Association and to register to virtually attend
the conference, visit
professional.diabetes.org/scientific-sessions.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to
helping people better manage their diabetes by developing and
marketing continuous glucose monitoring (CGM) products and tools
for adult and pediatric patients. With exceptional performance,
patient comfort and lifestyle flexibility at the heart of its
technology, users have consistently ranked DexCom highest in
customer satisfaction and loyalty. For more information, visit
www.dexcom.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210625005049/en/
Media Contact James McIntosh
619-884-2118 james.mcintosh@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jun 2024 to Jul 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jul 2023 to Jul 2024